Supportive Care

The FDA has approved eflapegrastim-xnst injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

Most hematology/oncology fellows will care for patients with venous thromboembolism throughout their training and long after their graduation from fellowship. Here are some practical considerations when treating a patient with an acute VTE.

For Dawn Hershman, MD, MS, research and medicine are art forms that she uses to uplift and inspire every day.

Advances in the treatment of solid tumors and hematologic malignancies have resulted in the development of thera-peutic regimens that can be administered at various points in a patient’s care.

Michelle Chi, MD and Jennifer R. Green, MD, share practical points for trainees to approach the initial evaluation for a bleeding-disorder patient.

The FDA has approved maribavir for the treatment of adult and pediatric patients aged 12 years and older weighing at least 35 kg who have post-transplant cytomegalovirus infection that does not respond to available antiviral treatment.

Unsurprisingly, the use of cannabis in patients with cancer appears to be increasing as more and more states are adopting cannabis legislation, both for medical and adult use.

The first-in-class small molecule HIF-PHI inhibitor roxadustat demonstrated promising efficacy with favorable tolerability when used in the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies, meeting the primary end point of the phase 2 WHITNEY trial.

The FDA has issued a complete response letter to Spectrum Pharmaceuticals regarding the biologics license application for eflapegrastimas a potential option for the management of chemotherapy-induced neutropenia.

Melissa (Kah Poh) Loh, BMedSci, MBBCh, BAO, discusses the challenges of utilizing geriatric assessment in oncology and steps that the ACCC resources can provide to institutions that want to incorporate geriatric assessment into practice.

The FDA has accepted a new drug application for maribavir for the treatment of post-transplant recipients with cytomegalovirus infection who are refractory and/or resistant to previous anti-CMV treatment.

November 16, 2020 - The combination of plinabulin and pegfilgrastim showed a statistically significant improvement in the rate of prevention of grade 4 neutropenia versus pegfilgrastim alone in patients with cancer undergoing chemotherapy.

Treatment with the CDK4/6 inhibitor trilaciclib prior to chemotherapy compared with placebo significantly reduced the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer.

Avatrombopag failed to meet the composite primary end point of avoiding platelet transfusions, chemotherapy dose reductions by 15% or greater, and chemotherapy dose delays by 4 days or more in patients with solid tumors and chemotherapy-induced thrombocytopenia.

To address disparities, it is important for institutions to embrace and promote the fostering of an inclusive culture and environment for healthcare professionals of all races and genders, and to adequately equip women specifically with the tools they need to achieve success in the field.

Plinabulin was found to be a more favorable option for the prevention of chemotherapy-induced neutropenia compared with pegfilgrastim during the coronavirus disease 2019 pandemic.

Shaily Shah, MD, discusses disease and treatment-related ocular toxicities that can arise in patients with cancer, specific management strategies for patients receiving belantamab mafodotin who develop ocular toxicities, and the importance of collaborative management of these patients.

The FDA has granted a breakthrough therapy designation to plinabulin for chemotherapy-induced neutropenia.

One of the main methods to address this disparity of cancer care is using community health workers and navigators to do the grassroots outreach.

Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, discusses the management of immune-related adverse effects in patients who are receiving treatment with checkpoint inhibitors.

One of the most important tasks that oncology nurses face is ensuring that patients are taking their medications consistently and correctly, and that adverse events are properly managed—specifically in those patients with breast cancer.

Judging from the drug pipeline, the future of oncology is oral chemotherapy.

Data suggest that up to 95% of patients with lung cancer score below the fiftieth percentile on sexual function during and after completion of cancer-directed therapy.

Efbemalenograstim alpha (F-627) has demonstrated strong and lasting benefit when used as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, meeting the primary and secondary end points of a phase 3 study.

Toby Campbell, MD, MSCI, discusses the nuances of palliative care in oncology.

Dawn L. Hershman, MD, MS, spotlights important data pertaining to cancer care delivery, prevention, symptom management, and survivorship that were presented at the 2020 ASCO Virtual Scientific Program.

Baseline physical activity and physical function prior to a cancer diagnosis or treatment affects survival, with evidence spanning across solid tumor types and hematologic malignancies.

The FDA has launched a new initiative called Project Patient Voice, which is a website that will serve as a source of publicly available information regarding patient-reported symptoms from cancer trials examining marketed treatments.

The FDA has approved burosumab-twza (Crysvita) injection for the treatment of patients aged 2 and older with tumor-induced osteomalacia, which is described as the development of tumors that cause weakened and softened bones.

The combination of plinabulin and pegfilgrastim showed a significant enhancement in the rate of grade 4 neutropenia prevention compared with pegfilgrastim alone in patients undergoing chemotherapy, meeting the primary end point of a prespecified interim analysis of the phase 3 PROTECTIVE-2 trial.